The stock of Elanco Animal Health Incorporated (NYSE:ELAN) decreased by -$0.25 on Monday to $24.02, down -1.01 percent. The last five days have seen an average of 3,901,879 shares of common stock traded. 8 times new highs were reached in the current year, with a fall of -$4.35. The average number of shares traded over the last 20 days was 5,164,479, while the average volume over the last 50 days totaled 4,196,226.
ELAN stock dropped -6.83% since last month. On 05/12/22, the company’s shares reached a one-month low of $20.51. The stock touched a high of $37.49 on 03/03/22, after rallying from a low of $20.51 in 52 weeks. The price of ELAN stock has declined by -14.48% or -$4.35 this year, reaching a new high 8 times. Still, the stock price is down -35.92% from the 52-week high.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
There have been 12 days since Elanco Animal Health Incorporated (ELAN) last reported insider trading activity on May 11. On May 11, Director BILBREY JOHN P acquired 10,000 shares at $22.03 each. This transaction resulted in the insider spending $220,284. On Mar 02, HOOVER R DAVID added 5,000 shares at a price of US$29.00. After the transaction, the insider now owns 115,000 shares. Director Anand Kapila K had earlier bought 1,000 shares on Mar 01 for $28.48 a share. The transaction was completed for $28,479.
Beta for the stock is 0.76. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 2.32, the price-to-book (PB) ratio of 1.56, and the price-to-cash flow ratio of 40.51.
For the three months ended March 30, Elanco Animal Health Incorporated’s quick ratio was 1.40, while its current ratio was 2.40, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending March 30 is 0.80, and the total debt to equity ratio is 0.81. As far as profitability goes, gross margin for the trailing twelve months is 56.30% percent. Elanco Animal Health Incorporated’s operating margin stood at -3.70% for the same period. Based on annual data, it had gross profit of $2.63 billion and revenue of $4.76 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. ELAN’s return on assets (ROA) during the last 12 months has been -2.20%. There was a -1.70% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -4.70%.
According to Elanco Animal Health Incorporated’s quarterly financial report for the quarter that ended March 30. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $1.23 billion, while revenues fell by -1.39% to $1.11 billion. It was predicted that Elanco Animal Health Incorporated’s quarterly earnings would be $0.36, but it ended up being $0.35, beating the consensus by 2.90%. EBITDA was $308.0 million for the quarter. At the end of Elanco Animal Health Incorporated’s most recent quarter ended March 30, its liabilities totaled 8.64 billion, while its total debt was $6.48 billion. Equity owned by shareholders amounts to $474.1 million.
Here’s a quick look at Elanco Animal Health Incorporated’s (ELAN) price momentum from a technical perspective. As of 20 May, the RSI 9-day stood at 52.94%, suggesting the stock is Neutral, with a 54.18% historical volatility rate.
The stochastic %K and %D were 67.76% and 62.11% respectively, while the average true range (ATR) was 0.94. Based on the 14-day stochastic reading of 73.49%, the RSI (14) reading is 49.03%. On the 9-day MACD Oscillator, the stock is at 0.83, and the 14-day reading is at 0.71.
In its analyst report released on November 18, 2021, Morgan Stanley began covering Elanco Animal Health Incorporated (NYSE: ELAN). The stock was rated as an Overweight by the brokerage firm. Analysts have assigned Elanco Animal Health Incorporated (ELAN) an Overweight rating. ELAN is a stock that is recommended for selling by 0 brokerage firms, while 5 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 6 others recommend it as a buy.
What is ELAN’s price target for the next 12 months?
The current consensus forecast for the stock is between $30.00 and $40.00, with a median target price of $32.00. In analyzing these forecasts, the average price target given by analysts for Elanco Animal Health Incorporated (ELAN) is $34.14.